Table of Contents
- Trial overview
- Who can join the study
- What is being tested
- Study phase and size
- Main safety endpoint
- Status and study setting
- Patient-friendly terms
Trial overview
This article covers one interventional study, which means researchers give a study treatment and then measure what happens.[1] The trial is testing ARI0008 in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG).[1]
The study title says it is an early phase trial designed to evaluate the safety of a combination treatment that includes dendritic cells pulsed with tumor lysate and CAR-T cells targeting IL13Ra2.[1] The brief summary also says this is a first-in-human administration, meaning it is the first time this treatment approach is given to people in this study.[1]
Who can join the study
The target population is patients with newly diagnosed DIPG.[1] The source data does not give more detailed eligibility rules such as age limits, prior treatment rules, or other medical requirements.[1]
The planned enrollment is 15 patients, so this is a small study group.[1] Small early studies are often used to learn about safety before larger trials are done.[1]
What is being tested
ARI0008 is being studied as part of a combined immunotherapy approach.[1] In this trial, it is listed as a drug for intrathecal use, which means it is given into the fluid around the brain and spinal cord.[1]
The other study treatments are DIPG-lysate, given by intradermal injection, and DIPG-DC, also given by intradermal injection.[1] The summary explains that the dendritic cells are pulsed with lysates from a pool of 8 DIPG K27M-positive tumor cell lines, and that the CAR-T cells are anti-IL13Ra2 CAR-T cells derived from T cells previously stimulated by dendritic cells.[1]
In simple terms, the trial is not studying ARI0008 alone.[1] It is studying ARI0008 together with other immune-based treatments to see whether this treatment plan can be given safely in this patient group.[1]
Study phase and size
This is a Phase 1 trial.[1] Phase 1 studies usually come early in clinical development and focus mainly on safety, not on proving that the treatment works better than standard care.[1]
The study is planned for 15 participants, which fits the early safety-testing goal of the trial.[1] Because the group is small, the study is meant to gather careful early information rather than answer all questions about benefit.[1]
Main safety endpoint
The primary outcome is the number of Grade 3–4 serious adverse events according to Common Toxicity Criteria from the start of treatment until the end of the study for each patient.[1] These are severe or very severe medical problems that happen during the trial and are tracked closely.[1]
This endpoint shows that the main question in the study is whether the treatment combination can be given safely.[1] The source data does not list other outcomes such as tumor response, survival, or quality-of-life measures.[1]
Status and study setting
The trial status is Authorised.[1] This means the study has been approved to proceed according to the source record.[1]
The trial is registered as NCT2024-514052-32-00 in the source data provided.[1] The record describes it as a first-in-human safety study in patients with DIPG.[1]
Patient-friendly terms
DIPG is a brain tumor that starts deep in the brainstem, an area that helps control important body functions.[1] The study uses immune-based treatments, which means it is trying to use the body’s immune system in a planned way against the tumor.[1]
Dendritic cells are immune cells that help teach the immune system what to recognize.[1] CAR-T cells are T cells changed in the lab so they can better find a chosen target on tumor cells, here IL13Ra2.[1]
Intradermal injection means a shot into the skin.[1] Intrathecal or intraventricular delivery means the treatment is given into fluid spaces around the brain and spinal cord, which is different from a regular injection into a muscle or vein.[1]
